1. Home
  2. KNSA vs UPBD Comparison

KNSA vs UPBD Comparison

Compare KNSA & UPBD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KNSA
  • UPBD
  • Stock Information
  • Founded
  • KNSA 2015
  • UPBD 1986
  • Country
  • KNSA United Kingdom
  • UPBD United States
  • Employees
  • KNSA N/A
  • UPBD N/A
  • Industry
  • KNSA Biotechnology: Pharmaceutical Preparations
  • UPBD Diversified Commercial Services
  • Sector
  • KNSA Health Care
  • UPBD Consumer Discretionary
  • Exchange
  • KNSA Nasdaq
  • UPBD Nasdaq
  • Market Cap
  • KNSA 1.7B
  • UPBD 1.7B
  • IPO Year
  • KNSA 2018
  • UPBD 1995
  • Fundamental
  • Price
  • KNSA $21.09
  • UPBD $32.99
  • Analyst Decision
  • KNSA Strong Buy
  • UPBD Buy
  • Analyst Count
  • KNSA 5
  • UPBD 6
  • Target Price
  • KNSA $36.60
  • UPBD $39.17
  • AVG Volume (30 Days)
  • KNSA 365.7K
  • UPBD 427.5K
  • Earning Date
  • KNSA 10-29-2024
  • UPBD 10-31-2024
  • Dividend Yield
  • KNSA N/A
  • UPBD 4.47%
  • EPS Growth
  • KNSA N/A
  • UPBD 833.06
  • EPS
  • KNSA N/A
  • UPBD 1.49
  • Revenue
  • KNSA $384,098,000.00
  • UPBD $4,259,426,999.00
  • Revenue This Year
  • KNSA $60.05
  • UPBD $9.86
  • Revenue Next Year
  • KNSA $36.32
  • UPBD $4.13
  • P/E Ratio
  • KNSA N/A
  • UPBD $21.53
  • Revenue Growth
  • KNSA 54.41
  • UPBD 7.43
  • 52 Week Low
  • KNSA $15.52
  • UPBD $26.50
  • 52 Week High
  • KNSA $28.15
  • UPBD $38.72
  • Technical
  • Relative Strength Index (RSI)
  • KNSA 34.36
  • UPBD 60.08
  • Support Level
  • KNSA $20.41
  • UPBD $31.63
  • Resistance Level
  • KNSA $21.55
  • UPBD $32.76
  • Average True Range (ATR)
  • KNSA 0.87
  • UPBD 1.06
  • MACD
  • KNSA -0.14
  • UPBD 0.09
  • Stochastic Oscillator
  • KNSA 21.90
  • UPBD 69.94

About KNSA Kiniksa Pharmaceuticals Ltd.

Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.

About UPBD Upbound Group Inc.

Upbound Group Inc is an omnichannel platform company committed to elevating financial opportunity for all through inclusive, and technology-driven financial solutions that address the evolving needs and aspirations of consumers. It has four operating segments; The Rent-A-Center Business segment operates lease-to-own stores, the Acima segment offers the lease-to-own transaction to consumers who do not qualify for financing from the traditional retailer, and also offers the lease-to-own transaction through virtual offering solutions across e-commerce, digital, and mobile channels, Mexico segment offers lease-to-own stores in Mexico. The franchising segment offers the sale of rental merchandise to its franchisees. The company derives a majority of its revenue from the Acima segment.

Share on Social Networks: